Literature DB >> 14616171

Effect of a novel 5-HT3 receptor agonist MKC-733 on upper gastrointestinal motility in humans.

N S Coleman1, L Marciani, E Blackshaw, J Wright, M Parker, T Yano, S Yamazaki, P Q Chan, K Wilde, P A Gowland, A C Perkins, R C Spiller.   

Abstract

BACKGROUND: Although 5-HT3 antagonists have been used to treat chemotherapy-induced emesis and diarrhoea-predominant irritable bowel syndrome, the effects of 5-HT3 agonists in humans are unknown. AIM: To determine the effect of MKC-733, a selective 5-HT3 receptor agonist, on upper gastrointestinal motility.
METHODS: Oral MKC-733 (0.2, 1 and 4 mg) was compared with placebo in three randomized, double-blind, cross-over studies in healthy males. Antroduodenal manometry was recorded for 8 h during fasting and 3 h post-prandially (n = 12). Gastric emptying and small intestinal transit were determined by gamma-scintigraphy (n = 16). Gastric emptying, accommodation and antral motility were determined by echoplanar magnetic resonance imaging (n = 12).
RESULTS: MKC-733 (4 mg) increased the number of migrating motor complexes recorded in the antrum and duodenum (P < 0.001), but had no effect on post-prandial motility. MKC-733 delayed scintigraphically assessed liquid gastric emptying (P = 0.005) and accelerated small intestinal transit (P = 0.038). Echoplanar magnetic resonance imaging confirmed the delayed gastric emptying (P < 0.001) and demonstrated a significant increase in cross-sectional area of the proximal stomach (P < 0.01).
CONCLUSIONS: MKC-733 delays liquid gastric emptying in association with relaxation of the proximal stomach, stimulates fasting antroduodenal migrating motor complex activity and accelerates small intestinal transit.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616171     DOI: 10.1046/j.1365-2036.2003.01797.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  23 in total

Review 1.  Pharmacology of serotonin: what a clinician should know.

Authors:  F De Ponti
Journal:  Gut       Date:  2004-10       Impact factor: 23.059

Review 2.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

Review 3.  Challenges to the therapeutic pipeline for irritable bowel syndrome: end points and regulatory hurdles.

Authors:  Michael Camilleri; Lin Chang
Journal:  Gastroenterology       Date:  2008-10-09       Impact factor: 22.682

4.  Glucose increases synaptic transmission from vagal afferent central nerve terminals via modulation of 5-HT3 receptors.

Authors:  Shuxia Wan; Kirsteen N Browning
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-18       Impact factor: 4.052

Review 5.  Classification and functions of enteroendocrine cells of the lower gastrointestinal tract.

Authors:  Ashok R Gunawardene; Bernard M Corfe; Carolyn A Staton
Journal:  Int J Exp Pathol       Date:  2011-04-25       Impact factor: 1.925

Review 6.  Frontiers in functional dyspepsia.

Authors:  Noel R Fajardo; Filippo Cremonini; Nicholas J Talley
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 7.  Irritable bowel syndrome: recent and novel therapeutic approaches.

Authors:  Viola Andresen; Michael Camilleri
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Aripiprazole an atypical antipsychotic protects against ethanol induced gastric ulcers in rats.

Authors:  Abdulrahman Al Asmari; Mohammed Arshaduddin; Ibrahim Elfaki; Saeed Kadasah; Abdulrahman Al Robayan; Saeed Al Asmary
Journal:  Int J Clin Exp Med       Date:  2014-08-15

9.  Glucose-dependent trafficking of 5-HT3 receptors in rat gastrointestinal vagal afferent neurons.

Authors:  T Babic; A E Troy; S R Fortna; K N Browning
Journal:  Neurogastroenterol Motil       Date:  2012-07-30       Impact factor: 3.598

10.  Effects of ondansetron on gastric tone and motility changes induced by a prolonged intraduodenal infusion of nutrients. Results of a placebo-controlled study.

Authors:  Guillaume Savoye; Maud Brung-Lefebvre; Mickael Bouin; Céline Maillot; Philippe Denis; Philippe Ducrotté
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.